SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPath is drawing attention after securing an order for more than 50,000 optical assemblies for drone cameras from an unnamed defense customer. Traders view it as a sign of counter-drone demand, though speculation that the customer is Leonardo DRS remains unconfirmed, and some investors remain cautious amid share-price weakness and upcoming earnings.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,546,266,383.70521. The last known price of Dogecoin is 0.07588453 USD and is up 0.89 over the last 24 hours. It is currently trading on 1543 active market(s) with $1,129,852,058.92 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoins choppy trading around the eight-cent area, including repeated slips below that level alongside weakness in other crypto and meme coins, dominates the discussion. Traders are split between expecting further downside and buying the dips or holding for a recovery, with no clear DOGE-specific catalyst emerging.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Traders are focused on Middle East LNG supply disruptions, including reported damage to Qatars export infrastructure and risks around the Strait of Hormuz, which they see as a potential long-term tailwind for U.S. LNG exporters such as NextDecade. The bullish view is tempered by concerns that Rio Grande LNG is still under construction and NEXT may not produce LNG until 2027, leaving execution, financing, and timing risks before it can benefit directly.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Discussion centers on Zebecs payroll and payments expansion, particularly its MoneyGram/Stellar connection and reported European and Robinhood Chain integrations, which bullish traders see as signs of growing adoption. Others argue that partnerships and reported business metrics have yet to translate into stronger, sustained demand for ZBCN, and complain that the tokens price remains weak.

Basic Attention Token (BAT) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Basic Attention Token has a current supply of 1,500,000,000 with 1,495,724,656.95260575 in circulation. The last known price of Basic Attention Token is 0.13064027 USD and is up 2.94 over the last 24 hours. It is currently trading on 591 active market(s) with $15,372,551.09 traded over the last 24 hours. More information can be found at https://basicattentiontoken.org/.

Basic Attention Token

BAT is drawing attention after a sharp rally alongside strength in other altcoins, with traders focused on whether technical momentum can sustain a breakout. Some see healthy consolidation and another leg higher, while others expect profit-taking or a pullback; no specific token catalyst is clearly confirmed.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.0006528 USD and is up 0.85 over the last 24 hours. It is currently trading on 193 active market(s) with $5,174,420.89 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

AMP is drawing attention after a sharp rally and volume surge, with traders noting its strength amid broader crypto weakness and debating whether the move can hold or will fade like previous pumps. Some bullish posts point to Flexa payments and Anvil collateral infrastructure as longer-term potential, but no single confirmed announcement is driving the discussion.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on volatile Dow moves and its relative performance versus the Nasdaq and S&P, with traders split between crash warnings and bullish dip-buying. Fed and interest-rate concerns, rising yields, and oil-related geopolitical risks recur as market explanations, but no single catalyst dominates.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after a breakout to a fresh 52-week high, with traders pointing to call-heavy options activity, short-covering potential and anticipation of Q3 results. Buyout speculationparticularly around Sanofiis prominent, but others see the move as pre-earnings positioning tied to BRIUMVIs growth and stress that no deal has been confirmed.

Cosmos (ATOM) is a cryptocurrency . Cosmos has a current supply of 538,743,080.257876. The last known price of Cosmos is 1.54934617 USD and is up 3.36 over the last 24 hours. It is currently trading on 999 active market(s) with $34,414,170.84 traded over the last 24 hours. More information can be found at https://cosmos.network/.

Cosmos

Cosmos ATOM is drawing attention amid persistent price weakness, with holders highlighting staking rewards and hoping for renewed adoption and an altcoin rebound. Bearish traders counter that token inflation and a fading ecosystem are weighing on the outlook; institutional-adoption and regulatory catalysts remain largely speculative in the discussion.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as the equal-weight S&P 500 has outperformed cap-weighted indexes amid weakness in mega-cap tech, with traders viewing the move as a rotation and broader market participation. Some see the strength and recent highs as a healthier rally, while others question whether breadth can hold or warn that the divergence may signal trouble.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Etsy's Outside Tailwinds Are Fading. Analysts Say Its Growth Is Speeding Up Anyway

Etsy beat Q3 estimates as GMS rose 8.8% and active buyers returned to growth. Analysts raised price targets and reiterated Buy ratings.read more...

ETSY Q3 Earnings Beat Estimates on GMS & Ads Growth, Revenues Rise Y/Y

Etsy beats Q3 earnings and revenue estimates as GMS and advertising strengthen, active buyers return to growth and management forecasts 5%-7% Q4 GMS gains.

Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?  

Equity

Investors responded positively to stronger financial performance and progress in medical research. 


Etsy Inc Reveals Rise In Q3 Profit

(RTTNews) - Etsy Inc (ETSY) revealed a profit for its third quarter that Increased, from the same period last year...

Etsy (ETSY) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Etsy Surges As Active Buyers Rebound for First Time in Two Years, AI Search Sparks Turnaround

Etsy stock climbs over 3% after crushing Q3 earnings with $1.00 per share, posting $692.5M in revenue, and adding 540,000 active buyers as AI search boosts sales.read more...

Etsy Stock Hits Over 3-Year Highs — Q3 Revenue Jumps 11%, CFO To Depart In 2027 

Etsy’s Q3 revenue rose 10.9% year over year to $692.47 million, while adjusted EPS came in at $1.00, beating consensus estimates of $668.05 million in revenue and $0.76 per share, respectively, according to Fiscal.AI.


Big Day for Econ Data, Hyperscaler Earnings

We have a solid slate of reports today, both of the earnings variety and regarding economic growth.

Compared to Estimates, Etsy (ETSY) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Etsy (ETSY) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Etsy (ETSY) Q3 Earnings and Revenues Top Estimates

Etsy (ETSY) delivered earnings and revenue surprises of +15.67% and +3.51%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Etsy reported Q3 2026 revenue of $692.47M, up 10.9%, GMS of $2.65B, up 8.8%, and Adjusted EBITDA of $210.36M, up 14.6%, for the quarter.

Etsy cites macroeconomic and tariff uncertainty that may reduce demand or hinder cross-border trade, a lower net income margin and higher payments fees, and intense competition from rivals that may develop AI-enabled offerings more quickly.

Etsy's marketplace GMS and GMS per active buyer increased; services revenue rose with higher Etsy Ads click volume; Depop's sale generated $1.4B and is expected to eliminate recurring cash outflows.

Etsy, Inc. operates online marketplaces that connect creative entrepreneurs with buyers worldwide. Its services include the operation of Etsy.com, a marketplace for unique and creative goods, as well as related e-commerce platforms and seller services. The company was founded in 2005 and is headquartered in New York, NY.

Etsy Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Etsy shares hit a three-year high of $94.49 after Q3 revenue rose 11%.&nbsp;</li><li>REPL stock climbed to a nearly two-year high as its new melanoma treatment gained early traction.&nbsp;</li><li>Genmab hit a record high after a cancer drug combination cut death risk by 50% in a late-stage trial.&nbsp;</li></ul><p>Etsy Inc. (ETSY), Replimune Group (REPL) and Genmab A/S (GMAB) stock hit fresh highs on Wednesday as stronger-than-expected earnings, early commercial traction for a newly launched treatment and positive late-stage cancer trial results fueled investor optimism, highlighting how company-specific catalysts are driving gains across consumer and biotechnology stocks.&nbsp;</p><p>Genmab and Replimune stocks surged 28% and 23%, respectively, while Etsy stock gained 5%.&nbsp;</p><h2 class="st-heading-2">Etsy Beats Earnings Estimates As Marketplace Trends Improve</h2><p><a href="https://stocktwits.com/symbol/ETSY">Etsy stock</a> reached a three-year high of $94.49 after the company reported an 11% year-over-year&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/etsy-stock-hits-over-3-year-highs-q3-revenue-jumps-11-cfo-to-depart-in-2027/cZU91ZYR9GJ">increase</a> in third-quarter revenue, surpassing analysts' expectations. The online marketplace also recorded its sixth consecutive quarter of improving gross merchandise sales growth, reflecting progress in attracting shoppers.&nbsp;</p><p>Goldman Sachs raised its price target on Etsy to $108 from $89 but kept a ‘Neutral’ rating, suggesting a 17% upside potential from its last closing price. Analyst Eric Sheridan cited better personalized shopping features and more effective marketing. Jefferies also increased its target to $100 from $90.&nbsp;</p><p>On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’.&nbsp;</p><h2 class="st-heading-2">Replimune Gains On Early Commercial Progress</h2><p><a href="https://stocktwits.com/symbol/REPL">Replimune stock</a> rose to nearly a two-year high of $16.75 as investors assessed initial demand for TUDRIQEV, the company's newly introduced melanoma treatment. The company said Doctors have started ordering the drug, and the company has enough stock to meet demand for more than a year. Replimune has contacted more than 70% of its first 200 target healthcare accounts to support the drug’s launch.&nbsp;</p><p>Jefferies analyst Roger Song raised his price target to $29 from $24 and retained a ‘Buy’ rating. The firm said that about three weeks after launch, the therapy gained formulary access at about 20 accounts, while more than 15 accounts began prescribing it. Song highlighted adoption by regional centers and the potential for further growth in prescribing activity, repeat use and treatment volume.</p><p>Retail sentiment around the stock remained ‘bullish’.&nbsp;</p><h2 class="st-heading-2">Genmab Advances Following Cancer Trial Results</h2><p><a href="https://stocktwits.com/symbol/GMAB">Genmab stock</a> reached an all-time high of $59.97 after announcing that a pivotal late-stage head and neck cancer study achieved its primary endpoints. The company reported that petosemtamab combined with pembrolizumab reduced the risk of death by 50% compared with pembrolizumab alone in patients with PD-L1-positive head and neck cancer, regardless of HPV status.&nbsp;</p><p>The findings could support upcoming regulatory submissions, potentially bringing the experimental treatment closer to the next stage of development.&nbsp;</p><p>So far this year, ETSY, REPL, and GMAB stocks have gained 65% to 86%.</p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wen-stock-heads-for-best-week-since-june-wendy-s-to-assess-peltz-s-1-4-b-bid-retail-expects-more-offers-to-come/cZUQ349R9Gv">WEN Stock Heads For Best Week Since June: Wendy's To Assess Peltz's $1.4B Bid, Retail Expects 'More Offers To Come'</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The logo of US e-commerce company Etsy Inc. is displayed on a smartphone in front of abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

Etsy Inc. (ETSY), Replimune Group (REPL) and Genmab A/S (GMAB) stock hit fresh highs on Wednesday as stronger-than-expected earnings, early commercial traction for a newly launched treatment and positive late-stage cancer trial results fueled investor opt

Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?

Genmab - ADR

Replimune Group Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ETSY News